For example, in Japan RET testing is generally performed within the context of clinical trials for patients with NSCLC, though there are indications that this is changing [19–22] and recent ESMO guidelines suggest earlier testing in certain scenarios [9]. Here, RET is linked to non-small cell lung carcinoma.